Commercialization deals are the new exit

In drug development, commercialization agreements have become the main way for new companies to create value.

In the drug development industry, where exits are rare, commercialization agreements have become the main way for new companies to create value. Last week provided an interesting example of just how big a commercialization agreement can be: Chiasma Ltd. will receive $65 million from Roche AG (SWX: ROG), and the amount could reach $600 million more in royalties. If the deal is implemented in full, it will be the biggest to date for an Israeli drug development company.

For a small drug development company, a commercialization agreement is usually attractive. The money goes to the till and can be used to develop other products. The deal supports the company's stability, survivability, and future potential.

The story is somewhat different for the company's investors. The do not get the proceeds immediately, and they depend on the deal boosting the company value. But commercialization deals are complicated and diversified, and it is not always possible to know how they will translate into company value. This and other issues related to commercialization deals were discussed at an investors panel moderated by Gelbart Kahana VP Eran Gabay.

In defining a commercialization deal, stem cell therapy developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) chairman and CEO Zami Aberman said, "A real commercialization deal is a deal in which money changes hands. Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) CEO Dr. Pnina Fishman said that the money changing hands immediately was not the only aspect, but that future payments and how they compare with other deals in the same sector and stage of development. "For example, a deal made after a Phase II clinical trial and less than 4% royalties, is unusually low," she said.

Most companies try to sign commercialization deals at an early stage of development in order to hand over full responsibility for the product to their partners. Alternatively, companies try to reach late-stage clinical trials and then to try and reach a bigger commercialization deal.

Intec Pharma Ltd. (TASE: INTP) is a developer of an accordion capsule to delay release of a drug in the intestine, rather than the stomach. EVP commercial operations Zeev Weiss said, "While we were independently developing our products for particular indications, we were approached by companies interested in financing development in fields we had always dreamed of, but we didn’t because of our limited resources. Even if we only obtain future royalties (which is not always the case), according to other companies, royalties of 7% of a billion dollar market, with almost no investment on our part, can translate into a company value of over $1 billion."

Weiss adds, "Working with big companies at early stages means adapting to their work methods, test and regulation levels, and ways of thinking. This moves the company forward dramatically in all kinds of ways."

The panelists cautioned that until a deal is signed, the other party is not a partner, but a competitor. Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP); DAX:OJU) is developing an insulin tablet. President and CEO Nadav Kidron said, "A big pharma company asked us to provide it with a sample of the insulin tablet that we developed. Another new company warned us and said that that company had asked them for a sample, and copied ideas from it. We therefore did not give the company a sample and the deal was not implemented. We could not take such a risk."

"We had a similar experience," said Aberman. "After negotiations with a corporation did not reach a deal, we heard that it was trying to develop something similar. We warned the company and it stopped the activity. It's important to protect ourselves because competition is the game."

Aberman added that Pluristem now only discloses its patents to strategic partners only between signing a term sheet and closing a deal. "This gives them the chance to withdraw if something is not OK, but we're pretty sure that they are serious," he says.

"We think that disclosure should wait until the end," said Fishman. "It would be very hard to close a deal if your partner cannot examine the technology in depth."

Aberman cited another risk of commercialization agreements, related to the partner's investment in the company's shares. "It gives the partner an edge in the company, and other investors don’t want to invest. In our case, because we're an Israeli company, we'd be asked if we'd already signed a deal with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), or in their words, 'Are you Teva's partner?' We have no agreement with it, but this shows the thinking."

Three of the four companies on the panel are traded in the US, and Gabay asked whether this facilitated a deal.

Fishman said, "The American capital market definitely exposed us to potential partners, and because there is expert analysis in this market, it gives investors confidence."

Weiss said that the important thing was to obtain good investors, but that commercialization deals were less influenced by the stock market on which a company was listed or by analysts' opinions. "Big companies come with their analysts, scientists, and marketers," he said. "There is not necessarily a link between what they think about a company and what the market thinks about it."

All the panelists agreed that all the company's financial soundness was important. The more a company is pressed for cash, it weaker is its bargaining position vis-à-vis a big pharma company. "There have been extreme cases in which big pharma companies exploited the fact that the young company facing them was listed on the TASE," said Weiss. "They signed a deal, the young company's share price rose, and then the big pharma company cancelled the deal, causing the share price to fall below what it was when the deal was signed. Shortly afterwards, a subsidiary of that big pharma company bought the product when the share price was at rock bottom. That's an extreme example."

"You then ask if it is worthwhile being a public company," said Aberman. "In my opinion, for the purposes of negotiations, it's better to be a private company, but because we're a public company, we've raised $130 million to date. What private party could give us so much money?"

Fishman added, "We also first raised capital from venture capital funds, which invested $8 million in us and were sure that a deal would immediately follow."

Aberman advised obtaining several offers from different companies. "This isn't a matter of picking up the phone, but a long and complex process. A deal can take three years to build. We take care to build these relations at an early stage so we can pick up the phone if we need to."

Published by Globes [online], Israel business news - www.globes-online.com - on February 24, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018